Literature DB >> 18072146

Insulin & C-peptide levels in sulfonylurea-induced hypoglycemia: a systematic review.

Christopher R DeWitt1, Kennon Heard, Javier C Waksman.   

Abstract

OBJECTIVES: We will describe insulin and C-peptide levels observed in sulfonylurea-induced hypoglycemia and determine whether these levels differed if obtained before or after hypoglycemic therapy.
METHODS: We performed a systematic review of the English literature to identify Medline articles containing "sets" (glucose <60 mg/dL with insulin and C-peptide levels). These "sets" were categorized as being obtained BEFORE, AFTER, or UNKNOWN with respect to hypoglycemic therapy.
RESULTS: 22 articles, 76 patients, and 97 "sets" were included. Mean glucose (mg/dL), insulin (muIU/mL), and C-peptide (ng/mL) for all "sets' were 28.6 (+/-12.6; 26.1 to 31.2), 54.4 (+/-126.3; 28.3 to 80.5), 7.2 (+/-6.2; 5.9 to 8.5). The BEFORE measures were 24.3 (+/-7.3; 18.7 to 30.0), 36.6 (+/-26.2; 16.5 to 56.7), 5.4 (+/-4.6; 1.5 to 9.2). The AFTER measures were 33.1 (+/-9.8; 28.2 to 38.0), 126.7 (+/-278.1; 0 to 265.0), 10.3 (+/-10.5; 5.1 to 15.4). The UNKNOWN measures were 28.0 (+/-13.5; 24.7 to 31.3), 37.1 (+/-21.8; 31.7 to 42.5), 6.5 (+/-4.3; 5.4 to 7.6). Only one "set" (glucose 49 mg/dL) had insulin <3.9 muIU/mL and C-peptide <1.4 ng/mL.
CONCLUSIONS: Insulin > or =3.9 muIU/mL, C-peptide > or =1.4 ng/mL, and glucose <49 mg/dl are consistent with sulfonylurea-induced hypoglycemia. BEFORE levels were lower, but they were consistent with sulfonylurea-induced hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18072146      PMCID: PMC3550061          DOI: 10.1007/bf03160920

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  40 in total

1.  A flaw in the use of sulfonylurea screening to diagnose sulfonylurea overdosages.

Authors:  David C Klonoff
Journal:  Diabetes Technol Ther       Date:  2003       Impact factor: 6.118

2.  Best practice No 173: clinical and laboratory investigation of adult spontaneous hypoglycaemia.

Authors:  R Gama; J D Teale; V Marks
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

3.  Diagnostic use of glucagon-induced insulin response. Studies in patients with insulinoma or other hypoglycemic conditions.

Authors:  D Kumar; S D Mehtalia; L V Miller
Journal:  Ann Intern Med       Date:  1974-06       Impact factor: 25.391

4.  Glucagon test for insulinoma: a chemical study in 25 cases.

Authors:  V Marks; E Samols
Journal:  J Clin Pathol       Date:  1968-05       Impact factor: 3.411

5.  Factors affecting insulin response to glucagon in man.

Authors:  N W Oakley; P Harrigan; A H Kissebah; E A Kissin; P W Adams
Journal:  Metabolism       Date:  1972-11       Impact factor: 8.694

6.  Pseudoinsulinoma syndrome from inadvertent tolazamide ingestion.

Authors:  D A Ahlquist; R L Nelson; C W Callaway
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

7.  An unusual cause of hyperinsulinaemic hypoglycaemia syndrome.

Authors:  P J Manning; E A Espiner; K Yoon; P L Drury; I M Holdaway; A Bowers
Journal:  Diabet Med       Date:  2003-09       Impact factor: 4.359

8.  Inadvertent sulfonylurea overdosage and hypoglycemia in an elderly woman: failure of serum hypoglycemia screening.

Authors:  Karen E Earle; Robert J Rushakoff; Ira D Goldfine
Journal:  Diabetes Technol Ther       Date:  2003       Impact factor: 6.118

9.  Identification of proinsulin and C-peptide in human serum by a specific immunoassay.

Authors:  F Melani; A H Rubenstein; P E Oyer; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1970-09       Impact factor: 11.205

10.  Screening for sulphonylureas in the investigation of hypoglycaemia.

Authors:  P Y P Kwong; J D Teale
Journal:  J R Soc Med       Date:  2002-08       Impact factor: 5.344

View more
  1 in total

1.  Diabetes management during Ramadan amid Covid-19 pandemic.

Authors:  Ali Tootee; Ensieh Nasli Esfahani; Bagher Larijani
Journal:  Daru       Date:  2020-06-25       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.